Status:
COMPLETED
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an open label Phase II Trial that using the investigational anti-cancer agent, Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size o...
Detailed Description
This multi-centered phase II trial will examine pazopanib stage IIIB/IV non-squamous NSCLC patients who have progressed on first-line therapy containing bevacizumab. Treatment should continue until di...
Eligibility Criteria
Inclusion
- Age 18 or older
- Stage IIIB (with malignant pleural or pericardial effusion or supraclavicular lymph node involvement) or stage IV NSCLC
- Evidence of progression while on bevacizumab
- Patients treated for CNS metastases who are asymptomatic with no requirement for steroids for 2 weeks prior to first dose of study drug
Exclusion
- Prior malignancy
- Clinically significant gastrointestinal abnormalities
- Presence of uncontrolled infection or nonhealing wound, fracture, or ulcer
- History of cardiovascular conditions within the past 6 months
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01262820
Start Date
December 1 2010
End Date
October 1 2014
Last Update
March 7 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
North Carolina Cancer Hospital at U of North Carolina at CH
Chapel Hill, North Carolina, United States, 27599
2
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232